Riddell Imogen A, Agama Keli, Park Ga Young, Pommier Yves, Lippard Stephen J
Department of Chemistry, Massachusetts Institute of Technology , Cambridge, Massachusetts 02139, United States.
Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, Maryland 20892, United States.
ACS Chem Biol. 2016 Nov 18;11(11):2996-3001. doi: 10.1021/acschembio.6b00565. Epub 2016 Oct 6.
Drugs capable of trapping topoisomerase II (Top2), an essential enzyme that cleaves DNA to remove naturally occurring knots and tangles, can serve as potent anticancer agents. The monofunctional platinum agent phenanthriplatin, cis-Pt(NH)(phenanthridine)Cl, is shown here to trap Top2 in addition to its known modes of inhibition of DNA and RNA polymerases. Its potency therefore combines diverse modes of action by which phenanthriplatin kills cancer cells. The observation that phenanthriplatin can act as a Top2 poison highlights opportunities to design nonclassical platinum anticancer agents with this novel mechanism of action. Such complexes have the potential to overcome current limitations with chemotherapy, such as resistance, and to provide treatment options for cancers that do not respond well to classical agents. Covalent DNA-platinum lesions implicated in Top2 poisoning are distinctive from those generated by known therapeutic topoisomerase poisons, which typically exert their action by reversible binding at the interface of Top2-DNA cleavage complexes.
能够捕获拓扑异构酶II(Top2)的药物可作为强效抗癌剂,拓扑异构酶II是一种 essential enzyme,它能切割DNA以消除自然产生的结和缠结。单功能铂剂菲咯啉铂,顺式-Pt(NH)(菲啶)Cl,在此显示除了已知的抑制DNA和RNA聚合酶的模式外,还能捕获Top2。因此,它的效力结合了菲咯啉铂杀死癌细胞的多种作用模式。菲咯啉铂可作为Top2毒药这一观察结果突出了设计具有这种新作用机制的非经典铂抗癌剂的机会。此类复合物有可能克服当前化疗的局限性,如耐药性,并为对经典药物反应不佳的癌症提供治疗选择。与Top2中毒相关的共价DNA-铂损伤与已知治疗性拓扑异构酶毒药产生的损伤不同,后者通常通过在Top2-DNA切割复合物界面的可逆结合发挥作用。